High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

• DOI: 10.1016/j.mcpro.2024.100749
• Publication Date: 2024-03-20T22:47:01Z
• Authors: Liyuan Dai; Qiaoyun Tan; Lin Li; Ning Lou; Cuiling Zheng; Jianliang Yang; Liling Huang; Shasha Wang; Rongrong Luo; Guangyu Fan; Tongji Xie; Jiarui Yao; Zhishang Zhang; Le Tang; Yuankai Shi; Xiaohong Han
• Keywords: Chemoimmunotherapy

Chemoimmunotherapy has evolved as a standard treatment for advanced non-small cell lung cancer (aNSCLC). However, inevitable drug resistance limited its efficacy, highlighting the urgent need biomarkers of chemoimmunotherapy. A three-phase strategy to discover, verify, and validate longitudinal predictive autoantibodies (AAbs) aNSCLC before after chemoimmunotherapy was employed. total 528 plasma samples from 267 patients anti-PD1 immunotherapy were collected, plus 30 independent formalin-fixed paraffin-embedded samples. Candidate AAbs firstly selected using HuProt high-density microarray containing 21,000 proteins in discovery phase, followed by validation an aNSCLC-focused microarray. Longitudinal chosen ELISA based on responders versus non-responders comparison progression-free survival (PFS) analysis. Prognostic markers also validated immunohistochemistry publicly available datasets. We identified panel two (MAX DHX29) pre-treatment another TAPBP) on-treatment undergoing All three exhibited positive correlation with early responses PFS (p < 0.05). The kinetics MAX AAb showed increasing trend 0.05) tendency initially increase then decrease Importantly, protein mRNA levels effectively discriminated treated immunotherapy. Our results present analysis changes prognostic